demonstration
human
leukocyte
degranulation
induced
serum
homozygote
heterozygote
cystic
fibrosis
ability
epsilon
amino
caproic
acid
eaca
treated
normal
serum
cystic
fibrosis
cf
affected
carrier
serum
promote
release
lysosomal
enzyme
sensitized
human
polymorphonuclear
leukocyte
pmn
assessed
measurement
beta
glucuronidase
myeloperoxidase
activity
exposure
cell
various
test
serum
study
initiated
extend
analogy
preciliary
dyskinesia
factor
pre
cdf
separated
cell
free
medium
culture
derived
cf
homozygous
heterozygous
individual
c
anaphylatoxin
extent
lysosomal
degranulation
human
pmn
exposed
fresh
untreated
serum
five
control
seven
cf
homozygote
eight
heterozygote
expressed
amount
beta
glucuronidase
release
control
serum
cf
affected
serum
heterozygous
serum
difference
cf
homozygote
control
subject
significant
p
le
difference
cf
affected
carrier
individual
le
p
le
control
subject
carrier
le
p
le
beta
glucuronidase
however
difference
control
subject
cf
heterozygous
individual
significant
treatment
serum
eaca
gave
value
beta
glucuronidase
myeloperoxidase
release
slightly
reduced
compared
obtained
fresh
untreated
sample
eaca
apparently
reduces
activity
beta
glucuronidase
released
pmn
amicon
filtration
study
serum
sample
demonstrated
degranulating
ability
presence
cilicary
dyskinesia
assessed
rabbit
tracheal
bioassay
always
associated
therefore
relationship
pre
cdf
degranulator
activity
native
cf
affected
carrier
serum
unclear
part
limitation
inherent
test
system
employed
